8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Nov 5, 2025·SEC
Material company update
Oct 27, 2025·SEC
X4 Pharmaceuticals, Inc.(XFOR)Earnings, Financials & Key Ratios
XFOR•NASDAQ
Price updated Jun 11, 2026
AboutX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.Show more
- Revenue$35M+1273.2%
- EBITDA-$86M-140.4%
- Net Income-$79M-111.5%
- EPS (Diluted)-1.87+66.5%
- Gross Margin82.18%+19.4%
- EBITDA Margin-243.8%+82.5%
- Operating Margin-247.44%+82.6%
- Net Margin-225.55%+84.6%
- ROE-75.99%+25.7%
- ROIC-143.12%-43.4%
- Debt/Equity0.41-88.2%
- Interest Coverage-9.79-202.5%
XFOR Key Insights
X4 Pharmaceuticals, Inc. (XFOR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 63.6%
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XFOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XFOR Price & Volume
X4 Pharmaceuticals, Inc. (XFOR) stock price & volume — 10-year historical chart
Loading chart...
XFOR Growth Metrics
X4 Pharmaceuticals, Inc. (XFOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years63.56%
3 Years-
TTM-71.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-783.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-313.15%
Return on Capital
10 Years-66.74%
5 Years-60.89%
3 Years-53.33%
Last Year-45.94%
XFOR Recent Earnings
X4 Pharmaceuticals, Inc. (XFOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 6, 2026EPS
$0.16
Est $0.20
+20.0%
Revenue
$2M
Est $3M
-22.8%
Q2 2026
Mar 17, 2026EPS
$0.22
Est $0.36
+38.9%
Revenue
$3M
Est $2M
+48.2%
Q4 2025
Nov 5, 2025EPS
$0.69
Est $0.79
+12.7%
Revenue
$2M
Est $2M
+1.8%
Q3 2025
Aug 8, 2025EPS
$3.47
Est $4.53
+23.4%
Revenue
$2M
Est $2M
-11.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.16vs $0.20+20.0% | $2Mvs $3M-22.8% |
| Q2 2026 | Mar 17, 2026 | $0.22vs $0.36+38.9% | $3Mvs $2M+48.2% |
| Q4 2025 | Nov 5, 2025 | $0.69vs $0.79+12.7% | $2Mvs $2M+1.8% |
| Q3 2025 | Aug 8, 2025 | $3.47vs $4.53+23.4% | $2Mvs $2M-11.4% |
Based on last 12 quarters of dataView full earnings history →
XFOR Peer Comparison
X4 Pharmaceuticals, Inc. (XFOR) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CYCN | 13.9M | 3.21 | -2.95 | 3.7% | -264.73% | -62.1% | ||
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARDX | 1.42B | 5.79 | -22.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 RARE | 2.36B | 23.98 | -4.11 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare XFOR vs Peers
X4 Pharmaceuticals, Inc. (XFOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XFOR Income Statement
X4 Pharmaceuticals, Inc. (XFOR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 3M | 0 | 0 | 0 | 2.56M | 35.11M | 9.01M |
Revenue Growth % | - | - | - | - | -100% | - | - | - | 1273.21% | -71.26% |
Cost of Goods Sold | 195K | 103K | 672K | 1.23M | 1.89M | 0 | 0 | 797K | 6.26M | 1.85M |
COGS % of Revenue | - | - | - | 41% | - | - | - | 31.17% | 17.82% | - |
Gross Profit | -195K▲ 0% | -103K▲ 47.2% | -672K▼ 552.4% | 1.77M▲ 363.4% | -1.89M▼ 206.9% | 0▲ 100.0% | 0▲ 0% | 1.76M▲ 0% | 28.86M▲ 1539.5% | 7.16M▲ 0% |
Gross Margin % | - | - | - | 59% | - | - | - | 68.83% | 82.18% | 79.44% |
Gross Profit Growth % | 35% | 47.18% | -552.43% | 363.39% | -206.89% | 100% | - | - | 1539.55% | - |
Operating Expenses | 35.94M | 28.98M | 46.13M | 61.64M | 73.46M | 87.57M | 107.52M | 38.16M | 115.74M | 104.91M |
OpEx % of Revenue | - | - | - | 2054.8% | - | - | - | 1492.41% | 329.62% | - |
Selling, General & Admin | 7.81M | 8.64M | 15.97M | 20.94M | 24.7M | 27.02M | 35.51M | 61.52M | 43.52M | 35.46M |
SG&A % of Revenue | - | - | - | 698.07% | - | - | - | 2405.87% | 123.93% | - |
Research & Development | 28.13M | 20.35M | 30.16M | 40.7M | 48.76M | 61.06M | 72.02M | 81.64M | 72.22M | 69.45M |
R&D % of Revenue | - | - | - | 1356.73% | - | - | - | 3192.92% | 205.69% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -509K | 0 | -105M | 0 | 0 |
Operating Income | -36.13M▲ 0% | -29.09M▲ 19.5% | -46.8M▼ 60.9% | -59.87M▼ 27.9% | -75.35M▼ 25.8% | -87.57M▼ 16.2% | -107.52M▼ 22.8% | -36.4M▲ 66.1% | -86.88M▼ 138.7% | -97.75M▲ 0% |
Operating Margin % | - | - | - | -1995.8% | - | - | - | -1423.58% | -247.44% | -1084.38% |
Operating Income Growth % | -48.41% | 19.51% | -60.92% | -27.93% | -25.85% | -16.22% | -22.79% | 66.15% | -138.68% | - |
EBITDA | -35.94M | -28.98M | -46.13M | -58.64M | -73.46M | -87.06M | -107.1M | -35.6M | -85.61M | -96.7M |
EBITDA Margin % | - | - | - | -1954.8% | - | - | - | -1392.45% | -243.8% | -1072.73% |
EBITDA Growth % | -49.46% | 19.36% | -59.17% | -27.12% | -25.26% | -18.51% | -23.03% | 66.76% | -140.43% | 13.91% |
D&A (Non-Cash Add-back) | 195K | 103K | 672K | 1.23M | 1.89M | 513K | 419K | 796K | 1.28M | 1.05M |
EBIT | -36.13M | -29.09M | -46.8M | -59.87M | -75.35M | -89.85M | -95.31M | -28.37M | -86.88M | -97.75M |
Net Interest Income | -1.86M | -484K | -950K | -2.42M | -3.63M | -3.77M | -1.2M | -3M | -4.3M | -3.15M |
Interest Income | 214K | 236K | 1.2M | 273K | 10K | 219K | 4.58M | 5.77M | 4.58M | 5.66M |
Interest Expense | 2.08M | 720K | 2.15M | 2.69M | 3.64M | 3.99M | 5.78M | 8.77M | 8.88M | 8.81M |
Other Income/Expense | 2.26M | -4.2M | -6M | -2.11M | -13.33M | -6.27M | 6.43M | -739K | 7.72M | -1.97M |
Pretax Income | -33.88M▲ 0% | -33.28M▲ 1.7% | -52.81M▼ 58.7% | -61.98M▼ 17.4% | -88.68M▼ 43.1% | -93.84M▼ 5.8% | -101.09M▼ 7.7% | -37.14M▲ 63.3% | -79.16M▼ 113.1% | -99.72M▲ 0% |
Pretax Margin % | - | - | - | -2066.1% | - | - | - | -1452.48% | -225.44% | -1106.22% |
Income Tax | 0 | 0 | 0 | 148K | 17K | 28K | 78K | 310K | 41K | 7K |
Effective Tax Rate % | 0% | 0% | 0% | -0.24% | -0.02% | -0.03% | -0.08% | -0.83% | -0.05% | -0.01% |
Net Income | -33.88M▲ 0% | -33.28M▲ 1.7% | -52.81M▼ 58.7% | -62.13M▼ 17.7% | -88.7M▼ 42.8% | -93.87M▼ 5.8% | -101.17M▼ 7.8% | -37.45M▲ 63.0% | -79.2M▼ 111.5% | -99.72M▲ 0% |
Net Margin % | - | - | - | -2071.03% | - | - | - | -1464.61% | -225.55% | -1106.3% |
Net Income Growth % | -47.45% | 1.75% | -58.65% | -17.66% | -42.76% | -5.83% | -7.78% | 62.98% | -111.48% | -783.12% |
Net Income (Continuing) | -33.88M | -33.28M | -52.81M | -62.13M | -88.7M | -93.87M | -101.17M | -37.45M | -79.2M | -99.72M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -17767.00▲ 0% | -14238.00▲ 19.9% | -138.94▲ 99.0% | -92.84▲ 33.2% | -119.58▼ 28.8% | -45.60▲ 61.9% | -17.07▲ 62.6% | -5.59▲ 67.3% | -1.87▲ 66.5% | -0.79▲ 0% |
EPS Growth % | -922.42% | 19.86% | 99.02% | 33.18% | -28.8% | 61.87% | 62.57% | 67.25% | 66.55% | -313.15% |
EPS (Basic) | -17767.00 | -14238.00 | -138.94 | -92.84 | -119.58 | -45.60 | -17.07 | -5.59 | -1.87 | - |
Diluted Shares Outstanding | 1.91K | 2.55K | 384.33K | 669.23K | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M | 126.29M |
Basic Shares Outstanding | 1.91K | 2.55K | 384.33K | 669.23K | 858.3K | 2.12M | 5.93M | 6.7M | 42.29M | 126.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XFOR Balance Sheet
X4 Pharmaceuticals, Inc. (XFOR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 79.53M | 9.34M | 129.28M | 83.31M | 87.88M | 128.68M | 122.08M | 112.17M | 261.58M | 241.98M |
Cash & Short-Term Investments | 76.79M | 8.13M | 126.18M | 78.97M | 81.79M | 121.72M | 114.22M | 102.06M | 253M | 233.72M |
Cash Only | 76.79M | 8.13M | 126.18M | 78.97M | 81.79M | 121.72M | 99.22M | 55.7M | 217.05M | 216.91M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 15M | 46.36M | 35.95M | 16.81M |
Accounts Receivable | 1.61M | 0 | 2M | 917K | 747K | 1.15M | 562K | 1.71M | 573K | 1.11M |
Days Sales Outstanding | - | - | - | 111.57 | - | - | - | 244.09 | 5.96 | 52.21 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.82M | 4.48M | 4.64M |
Days Inventory Outstanding | - | - | - | - | - | - | - | 1.29K | 261.28 | 805.93 |
Other Current Assets | 348K | 198K | 1.1M | 3.42M | 5.34M | 5.81M | 7.3M | 5.59M | 3.53M | 2.51M |
Total Non-Current Assets | 1.72M | 605K | 31.42M | 39.56M | 29.3M | 26.91M | 25.18M | 34.27M | 28.88M | 28.3M |
Property, Plant & Equipment | 421K | 241K | 2.36M | 9.2M | 10.22M | 8.33M | 6.39M | 4.84M | 1.59M | 1.18M |
Fixed Asset Turnover | - | - | - | 0.33x | - | - | - | 0.53x | 22.07x | 4.70x |
Goodwill | 0 | 0 | 27.11M | 27.11M | 17.35M | 17.35M | 17.35M | 17.35M | 17.35M | 17.35M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10M | 9.25M | 9.06M |
Long-Term Investments | 355K | 364K | 1.9M | 1.73M | 1.32M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 948K | 0 | 47K | 1.53M | 402K | 1.23M | 1.44M | 2.08M | 692K | 704K |
Total Assets | 81.25M▲ 0% | 9.94M▼ 87.8% | 160.7M▲ 1516.0% | 122.87M▼ 23.5% | 117.18M▼ 4.6% | 155.59M▲ 32.8% | 147.26M▼ 5.4% | 146.45M▼ 0.6% | 290.46M▲ 98.3% | 270.28M▲ 0% |
Asset Turnover | - | - | - | 0.02x | - | - | - | 0.02x | 0.12x | 0.04x |
Asset Growth % | 968.57% | -87.76% | 1516.03% | -23.54% | -4.63% | 32.78% | -5.35% | -0.55% | 98.34% | 147.96% |
Total Current Liabilities | 10.68M | 7.91M | 9.45M | 11.95M | 14.02M | 22.32M | 22.86M | 32.88M | 25.76M | 23.77M |
Accounts Payable | 1.89M | 2.97M | 2.09M | 3.14M | 4.28M | 7.78M | 8.95M | 8.62M | 5.7M | 5.07M |
Days Payables Outstanding | 3.54K | 10.52K | 1.13K | 932.98 | 826.27 | - | - | 3.95K | 332.27 | 1.16K |
Short-Term Debt | 2.31M | 1.69M | 898K | 786K | 1.87M | 1.31M | 0 | 0 | 0 | 733K |
Deferred Revenue (Current) | 694K | 737K | 0 | 0 | 0 | 0 | 0 | 0 | 464K | 2.72M |
Other Current Liabilities | 3.33M | 1.59M | 3.54M | 4.26M | 2.45M | 6.59M | 8.2M | 13.05M | 4.3M | 17.05M |
Current Ratio | 7.45x | 1.18x | 13.68x | 6.97x | 6.27x | 5.76x | 5.34x | 3.41x | 10.16x | 10.18x |
Quick Ratio | 7.45x | 1.18x | 13.68x | 6.97x | 6.27x | 5.76x | 5.34x | 3.33x | 9.98x | 9.98x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -2.41K | -65.04 | -300.63 |
Total Non-Current Liabilities | 11.87M | 13.71M | 22.03M | 38.12M | 38.74M | 59.21M | 73.3M | 91.42M | 78.41M | 78.06M |
Long-Term Debt | 9.92M | 8.14M | 20.1M | 33.18M | 33.14M | 32.3M | 54.57M | 75.42M | 76.29M | 0 |
Capital Lease Obligations | 0 | 0 | 1.92M | 4.48M | 4.78M | 3.6M | 2.61M | 1.41M | 0 | 910K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9K | 5.15M | 16K | 462K | 826K | 23.3M | 16.11M | 14.59M | 1.5M | 78.06M |
Total Liabilities | 22.55M | 21.62M | 31.48M | 50.07M | 52.76M | 81.53M | 96.16M | 124.3M | 104.17M | 101.83M |
Total Debt | 12.24M | 9.83M | 22.91M | 38.45M | 39.78M | 38.42M | 58.28M | 78.09M | 77.28M | 733K |
Net Debt | -64.56M | 1.7M | -103.27M | -40.52M | -42M | -83.3M | -40.94M | 22.39M | -139.76M | -216.18M |
Debt / Equity | 0.21x | - | 0.18x | 0.53x | 0.62x | 0.52x | 1.14x | 3.53x | 0.41x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.24x |
Interest Coverage | -17.38x | -40.40x | -21.80x | -22.27x | -20.69x | -22.50x | -16.50x | -3.24x | -9.79x | -11.10x |
Total Equity | 58.71M▲ 0% | -11.68M▼ 119.9% | 129.22M▲ 1206.6% | 72.8M▼ 43.7% | 64.41M▼ 11.5% | 74.05M▲ 15.0% | 51.1M▼ 31.0% | 22.15M▼ 56.7% | 186.29M▲ 741.1% | 168.45M▲ 0% |
Equity Growth % | 451.03% | -119.89% | 1206.62% | -43.66% | -11.52% | 14.96% | -30.99% | -56.65% | 741.08% | 1282.81% |
Book Value per Share | 30752.75 | -4581.01 | 336.22 | 108.78 | 75.05 | 34.97 | 8.62 | 3.30 | 4.40 | 1.33 |
Total Shareholders' Equity | 58.71M | -11.68M | 129.22M | 72.8M | 64.41M | 74.05M | 51.1M | 22.15M | 186.29M | 168.45M |
Common Stock | 15K | 0 | 16K | 16K | 28K | 122K | 167K | 6K | 91K | 94K |
Retained Earnings | -92.27M | -79.24M | -132.04M | -194.18M | -282.87M | -376.74M | -477.9M | -515.36M | -594.55M | -614.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 127K | 0 | -119K | -119K | -119K | -119K | -119K | -122K | -109K | -122K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XFOR Cash Flow Statement
X4 Pharmaceuticals, Inc. (XFOR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -27.87M | -25.42M | -48.05M | -58.82M | -70.91M | -77.1M | -96.51M | -130.9M | -85.62M | -92.85M |
Operating CF Margin % | - | - | - | -1960.6% | - | - | - | -5119.32% | -243.84% | - |
Operating CF Growth % | -28.8% | 8.79% | -89.04% | -22.4% | -20.55% | -8.74% | -25.17% | -35.63% | 34.59% | 13.97% |
Net Income | -33.88M | -33.28M | -52.81M | -62.13M | -88.7M | -93.87M | -101.17M | -37.45M | -79.2M | -99.72M |
Depreciation & Amortization | 195K | 103K | 672K | 1.23M | 1.89M | 513K | 419K | 796K | 1.28M | 1.04M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 5.2M | 8.69M | 8.2M | 4.3M | 3.78M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.39M | 4.63M | 7.32M | 6.15M | 17.4M | 5.32M | -4.79M | -105.13M | -9.42M | 3.77M |
Working Capital Changes | 3.42M | 3.13M | -3.24M | -4.06M | -1.5M | 5.74M | 344K | 2.67M | -2.58M | -1.71M |
Change in Receivables | -64K | -1.37M | 0 | 0 | 0 | 0 | 0 | -1.07M | 497K | -605K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.82M | -1.66M | -1.55M |
Change in Payables | 182K | 1.31M | -2.75M | 1.03M | 1.17M | 3.42M | 1.23M | -286K | -2.98M | -6.08M |
Cash from Investing | -42K | 0 | 27.23M | -1.36M | -615K | -103K | -14.88M | 66.99M | 8.15M | 30.54M |
Capital Expenditures | -42K | 0 | -174K | -1.36M | -615K | -103K | -60K | -326K | -3M | 0 |
CapEx % of Revenue | - | - | - | 45.4% | - | - | - | 12.75% | 8.54% | 0% |
Acquisitions | 0 | 0 | 26.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 1M | 0 | 0 | 0 | 0 | 98M | 0 | 0 |
Cash from Financing | 101.26M | 6.87M | 140.66M | 12.39M | 74.25M | 117.23M | 88.52M | 20.29M | 238.63M | 238.63M |
Debt Issued (Net) | 3.28M | -1.14M | 481K | 12.39M | 0 | -795K | 20.44M | 20M | 0 | 0 |
Equity Issued (Net) | 105.86M | 3.34M | 140.18M | 284K | 74.25M | 122.63M | 60M | 0 | 238.53M | 238.58M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -197K | -1.13M | 0 | 0 | -2M | 0 | 0 | 0 | 0 | 0 |
Other Financing | -7.87M | 4.67M | 0 | -278K | 0 | -4.61M | 8.08M | 294K | 98K | 54K |
Net Change in Cash | 73.76M▲ 0% | -68.66M▼ 193.1% | 118.05M▲ 271.9% | -47.21M▼ 140.0% | 2.81M▲ 106.0% | 39.92M▲ 1318.1% | -22.78M▼ 157.1% | -43.77M▼ 92.2% | 161.38M▲ 468.7% | 175.85M▲ 0% |
Free Cash Flow | -27.91M▲ 0% | -25.42M▲ 8.9% | -48.23M▼ 89.7% | -60.18M▼ 24.8% | -71.52M▼ 18.8% | -77.2M▼ 7.9% | -96.57M▼ 25.1% | -138.23M▼ 43.1% | -88.62M▲ 35.9% | -73.25M▲ 0% |
FCF Margin % | - | - | - | -2006% | - | - | - | -5405.83% | -252.38% | -812.62% |
FCF Growth % | -28.56% | 8.93% | -89.73% | -24.78% | -18.84% | -7.95% | -25.09% | -43.13% | 35.89% | 33.37% |
FCF per Share | -14621.79 | -9972.54 | -125.49 | -89.92 | -83.33 | -36.46 | -16.29 | -20.62 | -2.10 | -0.58 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.76x | 0.91x | 0.95x | 0.80x | 0.82x | 0.95x | 3.50x | 1.08x | 0.73x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 3.01M | 4.6M | 7.77M | 8.05M | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XFOR Key Ratios
X4 Pharmaceuticals, Inc. (XFOR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -161.38% | -141.55% | -89.85% | -61.51% | -129.28% | -135.58% | -161.67% | -102.26% | -75.99% | -94.9% |
| Return on Invested Capital (ROIC) | - | - | -439.6% | -154.25% | -206.68% | -997.9% | -17588.11% | -99.82% | -143.12% | -264.37% |
| Gross Margin | - | - | - | 59% | - | - | - | 68.83% | 82.18% | 79.44% |
| Net Margin | - | - | - | -2071.03% | - | - | - | -1464.61% | -225.55% | -1106.3% |
| Debt / Equity | 0.21x | - | 0.18x | 0.53x | 0.62x | 0.52x | 1.14x | 3.53x | 0.41x | 0.00x |
| Interest Coverage | -17.38x | -40.40x | -21.80x | -22.27x | -20.69x | -22.50x | -16.50x | -3.24x | -9.79x | -11.10x |
| FCF Conversion | 0.82x | 0.76x | 0.91x | 0.95x | 0.80x | 0.82x | 0.95x | 3.50x | 1.08x | 0.73x |
| Revenue Growth | - | - | - | - | -100% | - | - | - | 1273.21% | -71.26% |
Related:XFOR Dividend History·XFOR Revenue History·XFOR Price History·XFOR P/E History·XFOR Financial Ratios·XFOR Institutional Holders
XFOR SEC Filings & Documents
X4 Pharmaceuticals, Inc. (XFOR) SEC filings — annual & quarterly reports (10-K, 10-Q)
XFOR Frequently Asked Questions
X4 Pharmaceuticals, Inc. (XFOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
X4 Pharmaceuticals, Inc. (XFOR) reported $9.0M in revenue for fiscal year 2025.
X4 Pharmaceuticals, Inc. (XFOR) grew revenue by 1273.2% over the past year. This is strong growth.
X4 Pharmaceuticals, Inc. (XFOR) reported a net loss of $99.7M for fiscal year 2025.
Dividend & Returns
X4 Pharmaceuticals, Inc. (XFOR) has a return on equity (ROE) of -76.0%. Negative ROE indicates the company is unprofitable.
X4 Pharmaceuticals, Inc. (XFOR) had negative free cash flow of $73.3M in fiscal year 2025, likely due to heavy capital investments.